By: Our Staff Reporter
Ethiopia Today (Addis Ababa) June 1, 2026: Ethiopia is undergoing a major structural transformation, evolving from a strictly import-dependent market into a diversified pharmaceutical manufacturing hub.
After becoming the first country in the Intergovernmental Authority on Development (IGAD) region and only the ninth in Africa to achieve World Health Organization (WHO) Maturity Level 3 (ML3) for medicines regulation, local production has surged to exceed 40% of the national medicine supply.
The World Bank Group feature examines how rigorous regulatory standards, the purpose-built Kilinto Special Economic Zone, and cutting-edge research at AHRI and CDT-Africa are driving local job creation, regional exports, and long-term health sovereignty.
According to Heran Gerba, Director General of the Ethiopian Food and Drug Authority (EFDA), “Maturity Level 3 means that the regulatory system is stable and functioning well.” This milestone, achieved with the support of World Bank initiatives like the Ethiopia COVID-19 Emergency Response Project, ensures that medical products are systematically assessed against international safety and efficacy standards. A robust regulator not only builds domestic public trust but also accelerates market entry pathways during emergencies and unlocks regional trade opportunities. Under cross-border regulatory reliance frameworks, eight ML3 African nations have already agreed to recognize one another’s decisions, significantly shortening registration timelines under the AfCFTA and COMESA frameworks.
Infrastructure and Innovation Ecosystems
Regulation alone cannot sustain industrial growth; it requires dedicated infrastructure. At the 279-hectare Kilinto Special Economic Zone (SEZ) in Addis Ababa, Ethiopia, a specialized ecosystem has been developed explicitly tailored for pharmaceutical and medical equipment manufacturing.
“Kilinto is not only ideal for Ethiopia but also for Africa,” stated Tolossa Bedada, General Manager of the zone, noting that nearly 30 investors are currently at various stages ranging from factory construction to active commercial production.
This industrial infrastructure is tightly linked to domestic research and human capital development. “Unless we have a very strong research and development system, we cannot generate the knowledge needed to support pharmaceutical manufacturing,” emphasized Dr. Afework Kassu, Director General of the Armauer Hansen Research Institute (AHRI).
Backed by the World Bank Group, AHRI is currently establishing a bioequivalence center to certify that locally produced therapeutics meet international export requirements. Simultaneously, Addis Ababa University’s CDT-Africa, led by Professor Abebaw Fekadu, is training the next generation of translational scientists to build sustainable, continent-based know-how for manufacturing drugs, diagnostics, and vaccines.
While structural constraints such as limited access to foreign exchange and affordable finance persist, Ethiopia’s strategic goal remains to fulfill 50% of its essential medicine demand locally. This current milestone serves as an industrial springboard toward reaching Maturity Level 4, ensuring a highly resilient healthcare supply chain across East Africa.